Sitravatinib Clinical Program Initiates

Phase 1/1b clinical trials of sitravatinib, a multi-kinase inhibitor asset that originated with MethylGene, begin and continue to advance.

About Cookies on This Site

This website uses cookies. Essential and functional cookies are necessary for the proper functioning of this website and cannot be refused. Other cookies are used for statistical purposes and will only be placed if you agree to their placement. For further details on cookies, how we use cookies and how to modify your choices regarding cookies, please read our Cookies Policy.